this post was submitted on 17 Mar 2026
1 points (100.0% liked)

China News

103 readers
1 users here now

A community for china news

founded 5 months ago
MODERATORS
rss@news.abolish.capital
Salamence@lemmy.zip
RedWizard@news.abolish.capital
Salamence@mander.xyz
1
US reshoring drive casts shadow over China’s contract drug makers: analyst (www.scmp.com)
submitted 2 weeks ago by rss@news.abolish.capital to c/china@news.abolish.capital
0 comments fedilink hide all child comments
 

Chinese contract drug makers – including WuXi AppTec, WuXi Biologics and WuXi XDC – face a less certain long-term revenue outlook as US pharmaceutical companies bring production in-house and reconfigure supply chains amid rising US-China tensions. While near-term earnings remained largely locked in, visibility beyond that was limited, according to Cui Cui, head of healthcare research for Asia at Jefferies. “Earnings visibility for 2026 and 2027 is still very strong – revenue momentum is largely...

From China - South China Morning Post via This RSS Feed.

no comments (yet)
sorted by: hot top controversial new old
there doesn't seem to be anything here